CRPS specific Medication given fast-track approval by the FDA in March, 2015 and their study began in July of 2015!
You can read the article regarding their approval by clicking on the links below;
Axsome Therapeutics Announces FDA Fast Track Designation for AXS-02 for the Treatment of Pain Associated With Complex Regional Pain Syndrome
THE AXS-02 (oral zoledronate) STUDY
WHERE CAN I READ ABOUT THE STUDY AND APPLY TO BE PART OF IT?
Read about the AXS-02 Study, the specifics, and how to find out if you can qualify to be a part of it by clicking on the link below!
A Study to Assess the Efficacy and Safety of AXS-02 in Patients With CRPS-1
ClinicalTrials.gov identifier: NCT02504008
WHO IS THIS NEW MEDICATION DESIGNED TO HELP?
Patients who suffer from CRPS Type I, AKA RSDS. Remember, CRPS Type I is different from Type II. You can read about those differences HERE. The majority of those diagnosed with CRPS have Type I or what used to be known as RSDS, or Reflex Sympathetic Dystrophy.
There are some websites and Facebook pages on the internet with outdated definitions of these terms so please be sure your information is the most recent and correct.
WHAT KIND OF STUDY IS IT? HOW LONG WILL IT TAKE?
It is a randomized, placebo- controlled, double-blind, 24 week long study.
IMPORTANT INCLUSION FACTORS
Patients must be 18 years of age and be able to give written informed consent.
Patients must have a confirmed diagnosis of CRPS Type I.
Have a pain score of 5 or more on a scale of 0 to 10.
IMPORTANT EXCLUSION FACTORS
Patient had a sympathetic nerve block within 3 weeks.
Patient received chronic opiod therapy with 4 weeks.
Involved in active litigation or awaiting a workers’ compensation decision.
Any other clinically significant medical or pain condition (e.g., cognitive impairment or Fibromyalgia) or clinical abnormality that would, in the investigators judgement, interfere with the patients ability to participate in the study.
For more of the inclusion/exclusion criteria and other information regarding the study you can click on the link below.
